BridgeBio Pharma BBIO Deferred royalty obligations, net
Deferred royalty obligations, net at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:DeferredRoyaltyObligationNet.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's deferred royalty obligations, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's deferred royalty obligations, net?
- BridgeBio Pharma (BBIO) reported deferred royalty obligations, net of $871.19M in Q1 2026.
- How has BridgeBio Pharma's deferred royalty obligations, net changed year-over-year?
- BridgeBio Pharma's deferred royalty obligations, net increased by 75.2% year-over-year, from $497.3M to $871.19M.
- What does deferred royalty obligations, net mean?
- The net value of future royalty payments owed to third parties who provided upfront capital.
- How do you interpret deferred royalty obligations, net?
- A decrease indicates the gradual repayment of the obligation, while an increase suggests new royalty-based financing arrangements.
- How does deferred royalty obligations, net compare across companies?
- This is specific to companies that have utilized royalty monetization as a non-dilutive funding strategy.